For tumors not responding to standard chemotherapy as defined by overexpression of stromal signatures and FGFR1 target gene expression, the inhibition of FGFR activities by targeted approaches may be superior to predispose muscle-invasive bladder cancer to subsequent immune oncology treatment. The gene discussed is FGFR1; the disease is urinary bladder cancer.